Koji Masuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Koji Masuda has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Sakae Kaneko
Department of Dermatology Masuda Red Cross Hospital Masuda Japan
2 shared publications Ariane Dubost-Brama
Sanofi, Chilly-Mazarin, France
1 shared publication- Ashish Bansal
Regeneron Pharmaceuticals Inc. Tarrytown New York USA
1 shared publication - Atsushi Fukunaga
Department of Dermatology, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine Osaka Medical and Pharmaceutical University Osaka Japan
1 shared publication - Bolanle Akinlade
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A.
1 shared publication Chie Hashizume
Laboratory of Veterinary Ethology, The University of Tokyo
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 February 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 90 (6) , 1190-1199
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
- 1 February 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 90 (6) , 1190-1199
Top Cited PapersOpen AccessDupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
- Open Access
- 15 August 2021
- Published by Frontiers Media SA in Journal of Cutaneous Immunology and Allergy
- Vol. 5 (1) , 4-11
Current status of the satisfaction levels of adult patients receiving drugs for atopic dermatitis and chronic urticaria
Objectives: The satisfaction level of adult patients receiving drugs for atopic dermatitis and chronic urticaria is unclear. The objective of this multicenter study was to assess the satisfaction level of adult patients receiving treatment for allergic skin diseases, primarily atopic dermatitis and chronic urticaria.Methods: We developed a self‐administered questionnaire with multiple‐choice questions on patient characteristics, quality of life (QOL), and Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM‐9). We surveyed 302 patients receiving dermatological treatment.Results: The global satisfaction of patients (TSQM‐9) was lower for atopic dermatitis treatment compared with that for chronic urticaria. For atopic dermatitis, dupilumab had higher scores for effectiveness and global satisfaction, whereas topical tacrolimus and moisturizers had higher scores for convenience. For chronic urticaria, omalizumab had higher scores for effectiveness and global satisfaction, while antihistamines had a higher score for convenience. The Dermatology Life Quality Index was significantly associated with treatment effectiveness and global satisfaction, and patient satisfaction improved with the corresponding improvement in the QOL. For atopic dermatitis, satisfaction with dupilumab was higher than that with conventional standard therapy, after the confounding factors were eliminated. However, the same trend was not observed for chronic spontaneous urticaria.Conclusions: The satisfaction of the effectiveness for the biologic agents was higher, compared to that with conventional standard therapy. Treatment with biologics is worth exploring for patients who are not satisfied with their existing treatments.
- 15 August 2021
- Published by Frontiers Media SA in Journal of Cutaneous Immunology and Allergy
- Vol. 5 (1) , 4-11
Open AccessCurrent status of the satisfaction levels of adult patients receiving drugs for atopic dermatitis and chronic urticaria
Objectives: The satisfaction level of adult patients receiving drugs for atopic dermatitis and chronic urticaria is unclear. The objective of this multicenter study was to assess the satisfaction level of adult patients receiving treatment for allergic skin diseases, primarily atopic dermatitis and chronic urticaria.Methods: We developed a self‐administered questionnaire with multiple‐choice questions on patient characteristics, quality of life (QOL), and Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM‐9). We surveyed 302 patients receiving dermatological treatment.Results: The global satisfaction of patients (TSQM‐9) was lower for atopic dermatitis treatment compared with that for chronic urticaria. For atopic dermatitis, dupilumab had higher scores for effectiveness and global satisfaction, whereas topical tacrolimus and moisturizers had higher scores for convenience. For chronic urticaria, omalizumab had higher scores for effectiveness and global satisfaction, while antihistamines had a higher score for convenience. The Dermatology Life Quality Index was significantly associated with treatment effectiveness and global satisfaction, and patient satisfaction improved with the corresponding improvement in the QOL. For atopic dermatitis, satisfaction with dupilumab was higher than that with conventional standard therapy, after the confounding factors were eliminated. However, the same trend was not observed for chronic spontaneous urticaria.Conclusions: The satisfaction of the effectiveness for the biologic agents was higher, compared to that with conventional standard therapy. Treatment with biologics is worth exploring for patients who are not satisfied with their existing treatments.
- 19 September 2017
- Published by Morressier GmbH
Clinical features of urticaria in children.
Welcome to the largest platform for early-stage research
- 19 September 2017
- Published by Morressier GmbH
Clinical features of urticaria in children.
Welcome to the largest platform for early-stage research
- Open Access
- 13 November 2015
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 9 (1) , 256
Syringomatous adenoma of the nipple: a case report
Syringomatous adenoma of the nipple is a very rare benign tumor. To the best of our knowledge, there are no reports of a syringomatous adenoma of the nipple metastasizing, although these tumors are known to infiltrate locally and to recur if not totally resected. Our patient was a 41-year-old Japanese woman who complained of stiffness of her right nipple with abnormal discharge. Local resection of the tumor was performed. The pathological diagnosis was syringomatous adenoma of the nipple, and the resection margin was found to be positive. Accordingly, additional resection was recommended, but our patient did not allow another operation. After 1.5 years of careful follow-up, no local recurrence or distant metastasis has been observed. The optimal initial management of syringomatous adenoma of the nipple demands complete resection with histologically negative margins. However, from a cosmetic viewpoint, nipple-sparing resection could represent an alternative option for the treatment of syringomatous adenoma of the nipple.
- 13 November 2015
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 9 (1) , 256
Open AccessSyringomatous adenoma of the nipple: a case report
Syringomatous adenoma of the nipple is a very rare benign tumor. To the best of our knowledge, there are no reports of a syringomatous adenoma of the nipple metastasizing, although these tumors are known to infiltrate locally and to recur if not totally resected. Our patient was a 41-year-old Japanese woman who complained of stiffness of her right nipple with abnormal discharge. Local resection of the tumor was performed. The pathological diagnosis was syringomatous adenoma of the nipple, and the resection margin was found to be positive. Accordingly, additional resection was recommended, but our patient did not allow another operation. After 1.5 years of careful follow-up, no local recurrence or distant metastasis has been observed. The optimal initial management of syringomatous adenoma of the nipple demands complete resection with histologically negative margins. However, from a cosmetic viewpoint, nipple-sparing resection could represent an alternative option for the treatment of syringomatous adenoma of the nipple.
- 5 October 2015
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 22 (11) , 889-897
Rif1 binds to G quadruplexes and suppresses replication over long distances
ChIP-seq, biochemical and in vivo assays show that Rif1 binds G-rich motifs that can form G-quadruplex structures, thus regulating firing of proximal and distal DNA replication origins in fission yeast.
- 5 October 2015
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 22 (11) , 889-897
Rif1 binds to G quadruplexes and suppresses replication over long distances
ChIP-seq, biochemical and in vivo assays show that Rif1 binds G-rich motifs that can form G-quadruplex structures, thus regulating firing of proximal and distal DNA replication origins in fission yeast.
- Open Access
- 25 August 2014
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 172 (1) , 272-275
Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale‐8
- 25 August 2014
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 172 (1) , 272-275
Open AccessPoor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale‐8
- Open Access
- 1 January 2006
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 68 (2) , 157-159
Polymorphisms in the Canine Glutamate Transporter-1 Gene: Identification and Variation among Five Dog Breeds
Excitatory amino acid transporters (EAATs) are important for terminating glutamatergic neurotransmission and protect central nervous system (CNS) neurons from glutamatergic excitotoxicity. We selected these genes as targets that may relate to canine behavioral traits. After screening four EAAT genes (glutamate transporter-1; GLT-1, excitatory amino acid transporter 4; EAAT4, excitatory amino acid carrier; EAAC1, glutamate/aspartate transporter; GLAST) for single nucleotide polymorphisms (SNPs), we identified two silent SNPs (C129T and T471C) in the GLT-1 gene. We genotyped 193 dogs of 5 breeds and found significant variation among breeds in these two SNPs in GLT-1. The C129T polymorphism was not observed in Malteses and Miniature Schnauzers. These results suggest that polymorphisms in the GLT-1 gene may be useful markers for examining how the genetic background relates to the behavioral traits of dogs.
- 1 January 2006
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 68 (2) , 157-159
Open AccessPolymorphisms in the Canine Glutamate Transporter-1 Gene: Identification and Variation among Five Dog Breeds
Excitatory amino acid transporters (EAATs) are important for terminating glutamatergic neurotransmission and protect central nervous system (CNS) neurons from glutamatergic excitotoxicity. We selected these genes as targets that may relate to canine behavioral traits. After screening four EAAT genes (glutamate transporter-1; GLT-1, excitatory amino acid transporter 4; EAAT4, excitatory amino acid carrier; EAAC1, glutamate/aspartate transporter; GLAST) for single nucleotide polymorphisms (SNPs), we identified two silent SNPs (C129T and T471C) in the GLT-1 gene. We genotyped 193 dogs of 5 breeds and found significant variation among breeds in these two SNPs in GLT-1. The C129T polymorphism was not observed in Malteses and Miniature Schnauzers. These results suggest that polymorphisms in the GLT-1 gene may be useful markers for examining how the genetic background relates to the behavioral traits of dogs.